# A Study to Evaluate the Efficacy and Safety of PF-06480605 in Adults With Moderate to Severe Ulcerative Colitis

> **NCT04090411** · PHASE2 · COMPLETED · sponsor: **Hoffmann-La Roche** · enrollment: 246 (actual)

## Conditions studied

- Moderate to Severe Ulcerative Colitis

## Interventions

- **DRUG:** Induction- PF-06480605 50 mg SC Q4W
- **DRUG:** Induction- PF-06480605 150 mg SC Q4W
- **DRUG:** Induction- PF-06480605 450 mg SC Q4W
- **OTHER:** Induction- Placebo SC Q4W
- **DRUG:** Chronic- PF-06480605 50 mg SC Q4W
- **DRUG:** Chronic- PF-06480605 150 mg SC Q4W
- **DRUG:** Chronic- PF-06480605 450 mg SC Q4W

## Key facts

- **NCT ID:** NCT04090411
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-12-19
- **Primary completion:** 2022-10-25
- **Final completion:** 2022-10-25
- **Target enrollment:** 246 (ACTUAL)
- **Last updated:** 2025-12-16

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04090411

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04090411, "A Study to Evaluate the Efficacy and Safety of PF-06480605 in Adults With Moderate to Severe Ulcerative Colitis". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT04090411. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*